Table 1. Annotations of altered plasma proteins identified in the study [35]–[52].
| Gene Symbol | Protein | Peptides | Fold change | NormalCSF/Plasma | Signal/TM | Expression in tissue(Protein/mRNA) | Locali-zation |
| Upregulated proteins | |||||||
| APOD | Apolipoprotein D precursor | 3 | 2.2 | */+ | + | + | E |
| APOF | Apolipoprotein F precursor | 2 | 1.6 | */+ | + | + | E |
| APOM | Apolipoprotein M | 5 | 1.5 | */+ | + | + | E |
| CRP | C-reactive protein, pentraxin-related precursor | 3 | 5.1 | */+ | + | + | E |
| CA1 | Carbonic anhydrase 1 | 5 | 1.9 | */+ | – | + | C |
| CA2 | Carbonic anhydrase 2 | 4 | 2.1 | */+ | – | */+ | E |
| CPN1 | Carboxypeptidase N, polypeptide 1 precursor | 7 | 1.6 | */+ | + | + | E |
| CAT | Catalase | 4 | 1.8 | */+ | – | + | C |
| CAMP | Cathelicidin antimicrobial peptide | 3 | 1.8 | −/+ | + | */+ | E |
| CD14 | CD14 antigen precursor | 10 | 1.9 | */+ | + | */+ | E |
| CD5L | CD5 antigen-like precursor | 3 | 1.9 | */+ | + | + | E |
| CHGA | Chromogranin A precursor | 2 | 3.5 | */+ | + | + | E |
| F10 | Coagulation factor X preproprotein | 9 | 1.6 | */+ | + | + | E |
| F12 | Coagulation factor XII precursor | 13 | 1.7 | */+ | + | + | E |
| C1QA | Complement component 1, q subcomponent, A chain precursor | 3 | 1.9 | */+ | + | + | E |
| C4BPA | Complement component 4 binding protein, alpha chain precursor | 15 | 2.8 | */+ | + | + | E |
| C4BPB | Complement component 4 binding protein, beta chain isoform 2 precursor | 7 | 2.0 | −/+ | + | + | E |
| C4A | Complement component 4A preproprotein | 12 | 2.5 | */+ | + | */− | E |
| C7 | Complement component 7 precursor | 23 | 1.8 | */+ | + | + | E |
| CFHR3 | Complement factor H-related 3 isoform 1 precursor | 2 | 2.3 | */+ | + | – | E |
| CFHR5 | Complement factor H-related 5 precursor | 6 | 2.1 | −/+ | + | */+ | E |
| EFEMP1 | EGF-containing fibulin-like extracellular matrix protein 1 precursor | 5 | 1.5 | */+ | + | */+ | E |
| FTL | Ferritin, light polypeptide | 4 | 2.3 | */+ | – | */+ | C |
| FETUB | Fetuin-B precursor | 7 | 1.6 | */+ | + | + | E |
| BLVRB | Flavin reductase | 5 | 1.8 | −/+ | – | + | C |
| HP | Haptoglobin isoform 2 preproprotein | 2 | 5.6 | */+ | + | */+ | E |
| HBB | Hemoglobin subunit beta | 6 | 2.2 | */+ | – | */+ | E |
| HPX | Hemopexin precursor | 28 | 1.5 | */+ | + | */+ | E |
| HABP2 | Hyaluronan binding protein 2 preproprotein | 7 | 1.9 | */+ | + | + | E |
| KRT2 | Keratin 2 | 5 | 1.6 | */+ | – | */+ | C |
| LRG1 | Leucine-rich alpha-2-glycoprotein 1 precursor | 12 | 1.8 | */+ | + | + | E |
| MST1 | Macrophage stimulating 1 precursor | 11 | 1.8 | */+ | + | */+ | E |
| PRDX2 | Peroxiredoxin-2 isoform a | 5 | 1.6 | */+ | – | */+ | C |
| PLG | Plasminogen isoform 1 precursor | 43 | 1.8 | */+ | + | + | E |
| PVR | Poliovirus receptor isoform gamma | 2 | 1.7 | */+ | + | */+ | E |
| PROS1 | Protein S, alpha preproprotein | 10 | 1.5 | */+ | + | + | E |
| S100A9 | Protein S100-A9 | 4 | 1.6 | */+ | */+ | E | |
| F2 | Prothrombin preproprotein | 35 | 1.6 | */+ | + | */+ | E |
| SAA4 | Serum amyloid A-4 protein precursor | 2 | 1.5 | */+ | + | + | E |
| APCS | Serum amyloid P component precursor | 6 | 1.5 | */+ | + | + | E |
| UBC | Ubiquitin C | 3 | 1.6 | −/+ | + | C | |
| VCAM1 | Vascular cell adhesion protein 1 isoform a precursor | 3 | 1.5 | */+ | + | */+ | E |
| VTN | Vitronectin precursor | 9 | 1.6 | */+ | + | */+ | E |
| VWF | Von Willebrand factor preproprotein | 3 | 1.5 | */+ | + | */+ | E |
| Downregulated proteins | |||||||
| ALB | Albumin preproprotein | 8 | 0.7 | */+ | + | */+ | E |
| APOB | Apolipoprotein B precursor | 78 | 0.5 | */+ | + | + | E |
| APOC2 | Apolipoprotein C-II precursor | 4 | 0.7 | */+ | + | + | E |
| APOE | Apolipoprotein E precursor | 13 | 0.5 | */+ | + | */+ | E |
| CNDP1 | Carnosinase 1 precursor | 9 | 0.5 | */+ | + | – | C |
| C3 | Complement component 3 precursor | 6 | 0.63 | */+ | + | */− | E |
| C5 | Complement component 5 preproprotein | 40 | 0.63 | */− | + | + | E |
| IGFALS | Insulin-like growth factor binding protein, acid labile subunit isoform 2 precursor | 15 | 0.3 | */+ | + | + | E |
| ITIH1 | Inter-alpha (globulin) inhibitor H1 isoform a | 20 | 0.5 | */+ | + | + | E |
| ITIH2 | Inter-alpha globulin inhibitor H2 polypeptide | 24 | 0.3 | */+ | + | */+ | E |
| MAN1A1 | Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA | 3 | 0.5 | */+ | + | + | ER |
| LCP1 | Plastin-2 | 2 | 0.5 | */+ | + | C | |
| PPBP | Pro-platelet basic protein precursor | 5 | 0.7 | */+ | + | */+ | E |
| SERPINA10 | Serine proteinase inhibitor, clade A, member 10 precursor | 6 | 0.4 | */+ | + | + | E |
| SERPINA4 | Serine proteinase inhibitor, clade A, member 4 precursor | 15 | 0.6 | */+ | + | + | E |
| SOD3 | Superoxide dismutase 3, extracellular precursor | 2 | 0.5 | */+ | + | + | E |
| THBS1 | Thrombospondin 1 precursor | 16 | 0.6 | */+ | + | + | E |
Footnote:
E- Extracellular; C- Cytoplasm; ER- Endoplasmic reticulum.
In column 5 (*) indicates the earlier report of a protein identified in normal CSF and (+) in normal Plasma.
In column 7 (*) indicates expression of a protein in tissue at protein level (+) at mRNA level.
Protein localization, Signal/TM domain containing information was derived from HPRD [35] and information about presence in normal CSF or plasma was extracted from [36], [37] respectively. Expression of the genes/proteins at tissue level was inferred from published transcriptome dataset (master list; [38]) or protein datasets [39]–[52].